Novel therapeutics and targets in myelofibrosis

Julian A. Waksal, Claire N. Harrison, John O. Mascarenhas

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenias, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. Patients with MF also have a propensity toward leukemic transformation. Allogeneic hematopoietic stem cell transplantation (aHCT) is the only curative therapy for patients with MF; however, transplant-related morbidity and mortality precludes this option for the majority of patients. In the last decade, two targeted therapies have been approved for the treatment of MF, both JAK2 inhibitors, ruxolitinib and fedratinib. Despite the clinical efficacy of these two compounds in terms of splenomegaly and symptom burden reduction, there remain many areas of unmet need in the treatment of myelofibrosis. In this review, we discuss the limitations of currently approved treatment options and novel therapeutic targets with drug candidates in late-stage (phase II or III) clinical development for the treatment of MF. We delve into the mechanism of action and scientific rational of each candidate agent as well as the available clinical data, and ongoing trials that could lead to the approval of some of these novel therapies.

Original languageEnglish
Pages (from-to)1020-1033
Number of pages14
JournalLeukemia and Lymphoma
Issue number5
StatePublished - 2022


  • Myelofibrosis
  • clinical trials
  • novel targets
  • novel therapies
  • targeted therapy


Dive into the research topics of 'Novel therapeutics and targets in myelofibrosis'. Together they form a unique fingerprint.

Cite this